Methotrexate Pfizer

Methotrexate, the active ingredient in Methotrexate Pfizer, is an antimetabolite (folate antagonist) presented as an injectable solution for intramuscular, intravenous or intrathecal use. It is employed to treat autoimmune disorders and certain malignancies in adult and pediatric patients.

GNH USA supplies Methotrexate Pfizer as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Methotrexate acts on rapidly dividing cells and immune pathways, making it useful across several disease families. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: diminishes skin plaque formation and severity. - Acute lymphoblastic leukemia: interferes with leukemic cell proliferation. - Non‑Hodgkin lymphoma: contributes to tumor control in combination regimens. - Osteosarcoma: used as part of multi‑agent chemotherapy protocols.

Methotrexate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea or vomiting. - Fatigue or malaise. - Oral mucosal ulceration. - Transient elevation of liver enzymes. - Decreased white blood cell count. - Alopecia (hair thinning).

Serious or Rare Side Effects: - Pulmonary toxicity (interstitial pneumonitis). - Severe hepatic injury or fibrosis. - Bone marrow failure leading to pancytopenia. - Life‑threatening infections. - Renal impairment or failure. - Severe cutaneous reactions such as Stevens‑Johnson syndrome.

Methotrexate requires careful monitoring and specific safety measures. - Pregnancy: contraindicated (Category X) – avoid use in women of childbearing potential. - Liver function: monitor enzymes regularly; adjust therapy if significant elevation occurs. - Hematology: perform complete blood counts before and during treatment to detect cytopenias. - Renal function: assess creatinine clearance; dose reduction may be needed in impairment. - Folic acid supplementation: recommended to reduce mucosal and hematologic toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several drug classes, influencing efficacy and toxicity.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Penicillins and other β‑lactam antibiotics: may raise serum levels. - Sulfonamide antibiotics: potentiate hematologic suppression. - Live vaccines: risk of severe infection due to immunosuppression. - Proton pump inhibitors: can reduce renal clearance.

Moderate Interactions (Monitor Closely): - Warfarin: enhanced anticoagulant effect, monitor INR. - Phenytoin: may lower methotrexate concentrations. - Trimethoprim‑sulfamethoxazole: additive bone‑marrow suppression. - Azathioprine: combined immunosuppression increases infection risk. - Alcohol: exacerbates hepatic toxicity.